S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Magenta Therapeutics Stock Forecast, Price & News

-0.09 (-2.09%)
(As of 01/19/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
121,556 shs
Average Volume
299,970 shs
Market Capitalization
$247.45 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MGTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Magenta Therapeutics logo

About Magenta Therapeutics

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 17, 2015 and is headquartered in Cambridge, MA.


Big Pharma Is Going Holiday Shopping. Who's Next?
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.98 per share


Net Income
$-74.94 million
Pretax Margin




Free Float
Market Cap
$247.45 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.82 out of 5 stars

Medical Sector

826th out of 1,415 stocks

Pharmaceutical Preparations Industry

396th out of 682 stocks

Analyst Opinion: 3.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions

Is Magenta Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Magenta Therapeutics stock.
View analyst ratings for Magenta Therapeutics
or view top-rated stocks.

How has Magenta Therapeutics' stock been impacted by COVID-19?

Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MGTA stock has decreased by 54.0% and is now trading at $4.21.
View which stocks have been most impacted by COVID-19

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Magenta Therapeutics

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics, Inc. (NASDAQ:MGTA) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03.
View Magenta Therapeutics' earnings history

What price target have analysts set for MGTA?

6 brokers have issued twelve-month target prices for Magenta Therapeutics' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Magenta Therapeutics' share price to reach $15.00 in the next year. This suggests a possible upside of 256.3% from the stock's current price.
View analysts' price targets for Magenta Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the following people:
  • Jason Gardner, President, Chief Executive Officer & Director
  • Stephen Frank Mahoney, COO, CFO, Treasurer & Chief Accounting Officer
  • Lisa M. Olson, Chief Scientific Officer & Head-Research
  • David Nichols, Chief Technical Officer
  • Jeffrey S. Humphrey, Chief Medical Officer

What is Jason Gardner's approval rating as Magenta Therapeutics' CEO?

3 employees have rated Magenta Therapeutics CEO Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among Magenta Therapeutics' employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Who are Magenta Therapeutics' major shareholders?

Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Aries Wealth Management (0.07%). Company insiders that own Magenta Therapeutics stock include Bruce Booth and Kristen Stants.
View institutional ownership trends for Magenta Therapeutics

Which major investors are buying Magenta Therapeutics stock?

MGTA stock was bought by a variety of institutional investors in the last quarter, including Aries Wealth Management.
View insider buying and selling activity for Magenta Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $4.21.

How much money does Magenta Therapeutics make?

Magenta Therapeutics has a market capitalization of $247.45 million. The company earns $-74.94 million in net income (profit) each year or ($1.36) on an earnings per share basis.

How many employees does Magenta Therapeutics have?

Magenta Therapeutics employs 69 workers across the globe.

What is Magenta Therapeutics' official website?

The official website for Magenta Therapeutics is www.magentatx.com.

Where are Magenta Therapeutics' headquarters?

Magenta Therapeutics is headquartered at 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 242-0170 or via email at [email protected].

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.